Nonalcoholic fatty liver disease in Asia: A story of growth

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 18-23

  Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Liver fibrosis; NASH; Obesity; Transient elastography

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18;

ARTICLE; ASIA; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL;

EID: 84871652811     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12011     Document Type: Article

References (48)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
2. Wong VW, Chan HL, Hui AY etal. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment. Pharmacol. Ther. 2004; 20: 45-49.
3. Wong VW, Hui AY, Tsang SW etal. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 1154-1161.
4. Wong VW, Wong GL, Tsang SW etal. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J. Gastroenterol. Hepatol. 2008; 23: 914-921.
5. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42: 132-138.
6. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371-379.
7. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
8. Wong VW, Chu WC, Wong GL etal. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415.
9. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol. 2007; 22: 788-793.
10. Fan JG, Zhu J, Li XJ etal. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005; 43: 508-514.
11. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
12. Bhala N, Angulo P, van der Poorten D etal. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
13. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
14. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-777.
15. Wong VW, Wong GL, Tsang SW etal. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment. Pharmacol. Ther. 2009; 29: 387-396.
16. Wong VW, Chan HL. Transient elastography. J. Gastroenterol. Hepatol. 2010; 25: 1726-1731.
17. Wong GL, Wong VW, Choi PC etal. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035.
18. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
19. Nobili V, Vizzutti F, Arena U etal. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-448.
20. Yoneda M, Mawatari H, Fujita K etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Liver Dis. 2008; 40: 371-378.
21. Gaia S, Carenzi S, Barilli AL etal. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J. Hepatol. 2011; 54: 64-71.
22. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment. Pharmacol. Ther. 2011; 33: 1350-1360.
23. Wong GL, Wong VW, Chim AM etal. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J. Gastroenterol. Hepatol. 2011; 26: 300-305.
24. de Ledinghen V, Wong VW, Vergniol J etal. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J. Hepatol. 2012; 56: 833-839.
25. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
26. Wong VW, Wong GL, Chim AM etal. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am. J. Gastroenterol. 2008; 103: 1682-1688.
27. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078.
28. Shen J, Chan HL, Wong GL etal. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 2012; 56: 1363-1370.
29. Wong VW, Hui AY, Tsang SW etal. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 1215-1222.
30. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J. Gastroenterol. Hepatol. 2011; 26: 517-522.
31. Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2011; 26: 510-516.
32. Wong VW, Chan HL. Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test? J. Gastroenterol. Hepatol. 2011; 26: 419-420.
33. Wong VW, Wong GL, Yip GW etal. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727.
34. Athyros VG, Tziomalos K, Gossios TD etal. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922.
35. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003; 348: 1625-1638.
36. Wong VW, Wong GL, Tsang SW etal. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836.
37. Chan HL, de Silva HJ, Leung NW, Lim SG, Farrell GC. How should we manage patients with non-alcoholic fatty liver disease in 2007? J. Gastroenterol. Hepatol. 2007; 22: 801-808.
38. Johnson NA, Sachinwalla T, Walton DW etal. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
39. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J. Gastroenterol. Hepatol. 2009; 24: 399-407.
40. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129.
41. Wong VW, Chan RS, Wong GL etal. Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population-a randomised controlled trial. Gut 2012; 61 (Suppl. 2): A417.
42. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-1685.
43. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis-a systematic review and meta analysis. J. Hepatol. 2011; 55: 1383-1390.
44. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005; 142: 37-46.
45. Lippman SM, Klein EA, Goodman PJ etal. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
46. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-2471.
47. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
48. Ratziu V, Cadranel JF, Serfaty L etal. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J. Hepatol. 2012; 57: 376-383.